NSIS-B Stock Analysis: Novonesis (Novozymes) | CO
Specialty Chemicals | CO, Denmark | Market Cap: 197.551m DKK | 12M Return: 13% | DK0060336014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 237M
EPS Trend: 1.5%
Qual. Beats: -1
Rev. Trend: -84.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Novonesis (Novozymes) A/S is a Danish biotechnology company that produces and sells industrial enzymes, functional proteins, and microorganisms to customers across Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. The company operates a diversified B2B business model, supplying biosolutions to a wide range of industries rather than selling directly to end consumers.
Its products serve multiple end markets, including food and beverage (dairy, baking, beverages, plant-based foods), bioenergy (biodiesel, biogas, ethanol production), household and industrial cleaning, human health and nutrition, animal feed and pet care, agriculture (crop and silage solutions), textiles, and pulp and paper. The company also offers specific enzyme categories such as lipases, proteases, oxidoreductases, and carbohydrases, which are biological catalysts used to replace or enhance traditional chemical processes in manufacturing.
As a specialty chemicals company within the broader materials sector, Novonesis benefits from the growing demand for sustainable, bio-based alternatives to conventional industrial inputs. The company is headquartered in Lyngby, Denmark.
- Chr. Hansen merger synergies drive margin expansion
- Bioenergy enzyme demand grows on renewable diesel mandates
- Food and health biosolutions revenue scales post-merger
| Net Income: 631.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -5.11 > 1.0 |
| NWC/Revenue: 20.56% < 20% (prev 7.62%; Δ 12.95% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.32b > Net Income 631.8m |
| Net Debt (3.12b) to EBITDA (1.88b): 1.66 < 3 |
| Current Ratio: 1.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.2m) vs 12m ago -1.16% < -2% |
| Gross Margin: 54.89% > 18% (prev 58.42%; Δ -3.53% > 0.5%) |
| Asset Turnover: 26.02% > 50% (prev 70.48%; Δ -44.46% > 0%) |
| Interest Coverage Ratio: 10.74 > 6 (EBIT TTM 903.0m / Interest Expense TTM 84.1m) |
| A: 0.05 (Total Current Assets 2.08b - Total Current Liabilities 1.20b) / Total Assets 16.6b |
| B: 0.69 (Retained Earnings 11.4b / Total Assets 16.6b) |
| C: 0.05 (EBIT TTM 903.0m / Avg Total Assets 16.5b) |
| D: 2.04 (Book Value of Equity 11.2b / Total Liabilities 5.48b) |
| Altman-Z'' = 5.10 = AAA |
| DSRI: 2.91 (Receivables 931.4m/859.9m, Revenue 4.30b/11.6b) |
| GMI: 1.06 (GM 58.42% / 54.89%) |
| AQI: 0.98 (AQ_t 0.69 / AQ_t-1 0.70) |
| SGI: 0.37 (Revenue 4.30b / 11.6b) |
| TATA: -0.04 (NI 631.8m - CFO 1.32b) / TA 16.6b) |
| Beneish M = -1.86 (Cap -4..+1) = B |
As of October 07, 2026, the stock is trading at DKK 431.00 with a total of 861,973 shares traded. Over the past week, the price has changed by +2.91%, over one month by -1.12%, over three months by +4.49% and over the past year by +13.03%.
Current recommended Stop Loss: 418.70 (which is 2.9% or 1.2 ATR below the current price).
Novonesis (Novozymes) has no consensus analysts rating.
Market Cap EUR = 26.4b (198b DKK * 0.13378 DKK.EUR)
P/E Trailing = 41.7241
P/E Forward = 25.974
P/S = 45.9742
P/B = 2.447
P/EG = 2.016
Revenue TTM = 4.30b EUR
EBIT TTM = 903.0m EUR
EBITDA TTM = 1.88b EUR
Long Term Debt = 2.83b EUR (from longTermDebt, last quarter)
Short Term Debt = 237.3m EUR (from shortTermDebt, last quarter)
Debt = 3.44b EUR (from shortLongTermDebtTotal, last quarter) + Leases 369.0m
Net Debt = 3.12b EUR (calculated: Debt 3.44b - CCE 313.6m)
Enterprise Value = 29.6b EUR (26.4b + Debt 3.44b - CCE 313.6m)
Interest Coverage Ratio = 10.74 (Ebit TTM 903.0m / Interest Expense TTM 84.1m)
EV/FCF = 36.11x (Enterprise Value 29.6b / FCF TTM 818.4m)
FCF Yield = 2.77% (FCF TTM 818.4m / Enterprise Value 29.6b)
FCF Margin = 19.04% (FCF TTM 818.4m / Revenue TTM 4.30b)
Net Margin = 14.70% (Net Income TTM 631.8m / Revenue TTM 4.30b)
Gross Margin = 54.89% ((Revenue TTM 4.30b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 55.70% (prev 56.66%)
Tobins Q-Ratio = 1.78 (Enterprise Value 29.6b / Total Assets 16.6b)
Interest Expense / Debt = 2.45% (Interest Expense 84.1m / Debt 3.44b)
Taxrate = 21.32% (171.2m / 803.0m)
NOPAT = 710.5m (EBIT 903.0m * (1 - 21.32%))
Current Ratio = 1.74 (Total Current Assets 2.08b / Total Current Liabilities 1.20b)
Debt / Equity = 0.31 (Debt 3.44b / totalStockholderEquity, last quarter 11.2b)
Debt / EBITDA = 1.66 (Net Debt 3.12b / EBITDA 1.88b)
Debt / FCF = 3.82 (Net Debt 3.12b / FCF TTM 818.4m)
Total Stockholder Equity = 10.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.83% (Net Income 631.8m / Total Assets 16.6b)
RoE = 5.79% (Net Income TTM 631.8m / Total Stockholder Equity 10.9b)
RoCE = 6.57% (EBIT 903.0m / Capital Employed (Equity 10.9b + L.T.Debt 2.83b))
RoIC = 4.60% (NOPAT 710.5m / Invested Capital 15.5b)
WACC = 5.51% (E(26.4b)/V(29.9b) * Re(5.98%) + D(3.44b)/V(29.9b) * Rd(2.45%) * (1-Tc(0.21)))
Discount Rate = 5.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.73 | Cagr: 25.86%
[DCF] Terminal Value 73.10% ; FCFF base≈1.15b ; Y1≈1.01b ; Y5≈814.1m
[DCF] Fair Price = 24.09 (EV 13.1b - Net Debt 3.12b = Equity 9.94b / Shares 412.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 1.49 | EPS CAGR: 0.33% | SUE: -2.98 | # QB: -1
Revenue Correlation: -84.17 | Revenue CAGR: -50.18% | SUE: -0.69 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.19 | Chg30d=-42.25% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=16.13 | Chg30d=+0.13% | Revisions=+40% | GrowthEPS=+8.5% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=17.89 | Chg30d=+0.72% | Revisions=+46% | GrowthEPS=+10.9% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +48% (up=17, down=5)